
    
      The study is in four parts. Part A is up to 6 single ascending intravenous dose cohorts of
      STT-5058 in otherwise healthy volunteers with TRGs >150mg/dL. Part B is up to 4 multiple
      ascending intravenous doscohorts of STT-5058 in otherwise healthy volunteers with TRGs
      >150mg/dL who will receive 3 doses at 2 week intervals. Part C will recruit a single cohort
      of patient volunteers with TRG >200mg/dL who will receive 3 doses at 2 week intervals of
      STT-5058. Part D will investigate up to 2 single ascending doses of subcutaneous STT-5058
    
  